Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
Services professionnels
Témoignages clients
Newsroom
Blog
Rapport mondial sur l'innovation
Glossaire
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport How AI is transforming systematic literature review for technology platform development — faster screening, smarter synthesis, and patent-aware R&D workflows.
Article | Rapport Explore the 2026 copper alloy materials landscape for EV motor windings and power connectors. Key IP spaces, technology gaps, and dominant material strategies.
Article | Rapport A deep analysis of edge AI inference accelerator technology in 2026: dedicated silicon, FPGA, PIM architectures, NAS, and distributed inference across 80+ patent and literature records.
Article | Rapport Fenebrutinib vs. tolebrutinib: how CNS-penetrant BTK inhibitors target smoldering lesions and microglia in progressive MS. Phase III data signals analysed.
Article | Rapport The 2026 nickel superalloy landscape for gas turbine blades and additive manufacturing: key data sources, research gaps, and how to retrieve patent intelligence.
Article | Rapport TGA vs DSC for polymer degradation: understand which thermal analysis technique reveals mass loss, heat flow, or transition data—and when to use both together.
Article | Rapport Monopile foundations dominate 80% of offshore wind capacity. Explore the 2026 technology landscape: PISA models, TP-less designs, XXL monopiles, and key patents.
Article | Rapport Explore the key technical barriers to cost-competitive direct lithium extraction (DLE) from geothermal brine, from ion selectivity to scaling challenges.
Article | Rapport Dostarlimab (Jemperli) PD-1 inhibitor Phase III expansion in dMMR endometrial and colorectal cancer: GSK's biomarker-driven immunotherapy strategy explained.
Article | Rapport Titanium alloy patent landscape 2026: aerospace lightweighting and medical implants. Key alloy systems, IPC codes, assignees, and how to build a rigorous IP dataset.
Article | Rapport Explore the 2026 thermoelectric materials landscape: Bi₂Te₃, PbTe, and Half-Heusler alloys for waste heat recovery. Patent trends, ZT advances, and IP intelligence.
Article | Rapport Belantamab mafodotin (Blenrep) Phase III DREAMM readouts, reformulated combinations, and the GSK vs. daratumumab BCMA race in multiple myeloma.
Article | Rapport A 2026 technology landscape of continuous wearable blood pressure monitors: PTT, PPG, edge AI, ISO compliance, and key patent assignees mapped from 2012–2025 filings.
Article | Rapport How do model-based and measurement-based EMF simulation methods differ for vehicle antenna placement? A technical guide for automotive RF and EMC engineers.
Article | Rapport Depemokimab (Exdensur), GSK's ultra-long-acting anti-IL-5 biologic, offers twice-yearly dosing for severe asthma and CRSwNP. Explore the competitive IL-5 inhibitor landscape.